Skip to content

Author

Jie-Ru Han

We have 5 of 42 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Sep 2026

The Mechano-Immune-Vascular Activation Loop: An Integrative Conceptual Framework for Positive Feedback in Hypertension

Hypertension is increasingly recognized as involving chronic inflammation beyond its hemodynamic origins. This review proposes the Mechano-Immune-Vascular Activation Loop as an integrative conceptual framework—a positive feedback circuit in which aberrant mechanical forces in the hypertensive vascular wall may activate...

Shuang Gao, Bei-Yan Chen, Xin Chen et al. · 0 citations
Meta-analysis Open access Sep 2026

Incremental effects of SGLT2 inhibitors, GLP-1 receptor agonists, and pioglitazone in type 2 diabetes and MASLD across Asian study settings: a systematic review and meta-analysis

Objective We evaluated the incremental hepatic and metabolic effects of adding sodium–glucose cotransporter 2 (SGLT2) inhibitors, glucagon-like peptide-1 receptor agonists (GLP-1RAs), or pioglitazone to comparable background glucose-lowering therapy in Asian adults with type 2 diabetes mellitus (T2DM) and metabolic dys...

Han-Wen Zheng, Jie-Ru Han · 0 citations
Review Open access Aug 2026

Lactate as a Master Regulator of Immune Suppression: From Metabolic Waste to Epigenetic Checkpoint in Colorectal Cancer

Targeting lactate metabolism through LDHA or MCT4 inhibition, modulation of histone lactylation, or disruption of lactate-lipid crosstalk, when combined with classical immune checkpoint blockade and guided by spatial biomarkers, offers a promising strategy to overcome immunotherapy resistance in this challenging subtyp...

Bei-Yan Chen, Shuang Gao, Xin Chen et al. · 0 citations
Open access Sep 2026

Integrated Metabolic and Immune Molecular Subtyping and a Molecular Classification Score for Revealing Disease Heterogeneity in Pulmonary Arterial Hypertension

MIRS provides a molecular stratification basis for subtype discrimination and a hypothesis-generating framework for future therapeutic investigations and failed to discriminate PAH from controls in PBMCs, indicating that this tissue-derived signature is not readily detectable in peripheral blood.

Xin Chen, Yue-Tong Zhu, Qing-Ping Shi et al. · 0 citations
Open access Aug 2026

Exploring the Molecular Mechanism of Cinnamaldehyde Intervening in Ochratoxin A-Induced Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease Comorbidity: An Integrated Approach Based on Network Pharmacology, Network Toxicology and Molecular Docking

An integrated network toxicology and network pharmacology approach was employed to jointly decipher the potential mechanisms by which CA intervenes in OTA-induced comorbid T2DM-NAFLD comorbidity.

Ming-Li Shen, Qing-Ping Shi, Shuang Gao et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.